Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Recommendation of “Hold” by Brokerages

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been assigned an average recommendation of “Hold” from the five analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $9.3333.

A number of brokerages have recently weighed in on AYTU. Wall Street Zen cut shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Maxim Group dropped their target price on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, September 25th. Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, November 24th. Ascendiant Capital Markets raised their price target on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th.

Hedge Funds Weigh In On Aytu BioPharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP bought a new stake in Aytu BioPharma in the third quarter valued at about $58,000. FNY Investment Advisers LLC bought a new position in Aytu BioPharma during the second quarter worth about $78,000. Persistent Asset Partners Ltd bought a new position in Aytu BioPharma during the third quarter worth about $117,000. Two Sigma Investments LP boosted its holdings in Aytu BioPharma by 96.2% during the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after purchasing an additional 33,701 shares in the last quarter. Finally, Kanen Wealth Management LLC bought a new stake in shares of Aytu BioPharma in the 2nd quarter valued at approximately $1,250,000. 33.49% of the stock is owned by institutional investors.

Aytu BioPharma Stock Down 3.2%

AYTU stock opened at $2.45 on Friday. The firm has a market cap of $24.97 million, a price-to-earnings ratio of -0.80 and a beta of 0.28. Aytu BioPharma has a 1-year low of $0.95 and a 1-year high of $2.82. The firm has a fifty day moving average price of $2.23 and a two-hundred day moving average price of $2.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.23 and a quick ratio of 1.08.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Aytu BioPharma had a positive return on equity of 17.86% and a negative net margin of 20.52%.The company had revenue of $13.89 million during the quarter, compared to analyst estimates of $17.92 million.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.